M6223 not checked
EMD Serono Research & Development Institute, Inc.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants intravenous infusion of M6223 at dose of 1600 mg once every 2 weeks until unacceptable toxicity, withdraw consent or initiation of a new treatment.”In the company’s words, NCT05327530 on ClinicalTrials.gov
- Main trialPhase 2
- “The purpose of this study is to assess the safety and efficacy of avelumab in combination with other anti-tumor agents as a maintenance treatment in participants with bladder cancer.”In the company’s words, NCT05327530 on ClinicalTrials.gov
Other drugs for Locally Advanced or Metastatic Urothelial Carcinoma
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- Cretostimogene GrenadenorepvecCG Oncology, Inc. · Phase 3
- Disitamab vedotinPfizer · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- Disitamab VedotinRemeGen · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 20 Jun 2025 | A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) | |
| Phase 1Completed | 23 Jun 2023 | First in Human Study of M6223 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026